1241 related articles for article (PubMed ID: 26523330)
1. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
[TBL] [Abstract][Full Text] [Related]
2. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
[TBL] [Abstract][Full Text] [Related]
3. Effect of GnRHa ovulation trigger dose on follicular fluid characteristics and granulosa cell gene expression profiles.
Vuong TNL; Ho MT; Ha TQ; Jensen MB; Andersen CY; Humaidan P
J Assist Reprod Genet; 2017 Apr; 34(4):471-478. PubMed ID: 28197932
[TBL] [Abstract][Full Text] [Related]
4. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
[TBL] [Abstract][Full Text] [Related]
5. Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates.
Griffin D; Feinn R; Engmann L; Nulsen J; Budinetz T; Benadiva C
Fertil Steril; 2014 Aug; 102(2):405-9. PubMed ID: 24842671
[TBL] [Abstract][Full Text] [Related]
6. Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist.
Lu X; Hong Q; Sun L; Chen Q; Fu Y; Ai A; Lyu Q; Kuang Y
Fertil Steril; 2016 Nov; 106(6):1356-1362. PubMed ID: 27490046
[TBL] [Abstract][Full Text] [Related]
7. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
[TBL] [Abstract][Full Text] [Related]
8. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
[TBL] [Abstract][Full Text] [Related]
9. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles.
Lee JR; Kim SH; Kim SM; Jee BC; Ku SY; Suh CS; Choi YM; Kim JG; Moon SY
Fertil Steril; 2008 Apr; 89(4):860-7. PubMed ID: 18249372
[TBL] [Abstract][Full Text] [Related]
10. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
11. Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?
Lainas GT; Lainas TG; Sfontouris IA; Chatzimeletiou K; Venetis CA; Bosdou JK; Tarlatzis BC; Grimbizis GF; Kolibianakis EM
Hum Reprod; 2019 Sep; 34(9):1770-1777. PubMed ID: 31384921
[TBL] [Abstract][Full Text] [Related]
12. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial.
Lefebvre J; Antaki R; Kadoch IJ; Dean NL; Sylvestre C; Bissonnette F; Benoit J; Ménard S; Lapensée L
Fertil Steril; 2015 Dec; 104(6):1419-25. PubMed ID: 26361207
[TBL] [Abstract][Full Text] [Related]
13. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders.
Bar-Hava I; Mizrachi Y; Karfunkel-Doron D; Omer Y; Sheena L; Carmon N; Ben-David G
Fertil Steril; 2016 Aug; 106(2):330-3. PubMed ID: 27114332
[TBL] [Abstract][Full Text] [Related]
14. Ultrashort gonadotropin-releasing hormone agonist combined with flexible multidose gonadotropin-releasing hormone antagonist for poor responders in in vitro fertilization/embryo transfer programs.
Orvieto R; Kruchkovich J; Rabinson J; Zohav E; Anteby EY; Meltcer S
Fertil Steril; 2008 Jul; 90(1):228-30. PubMed ID: 17681292
[TBL] [Abstract][Full Text] [Related]
15. In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols.
Farhi J; Ben-Haroush A; Lande Y; Sapir O; Pinkas H; Fisch B
Fertil Steril; 2009 Feb; 91(2):377-82. PubMed ID: 18321490
[TBL] [Abstract][Full Text] [Related]
16. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).
Olivennes F; Belaisch-Allart J; Emperaire JC; Dechaud H; Alvarez S; Moreau L; Nicollet B; Zorn JR; Bouchard P; Frydman R
Fertil Steril; 2000 Feb; 73(2):314-20. PubMed ID: 10685535
[TBL] [Abstract][Full Text] [Related]
17. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.
Itskovitz-Eldor J; Kol S; Mannaerts B
Hum Reprod; 2000 Sep; 15(9):1965-8. PubMed ID: 10966996
[TBL] [Abstract][Full Text] [Related]
18. Association between body mass index and oocyte maturation in patients triggered with GnRH agonist who are at high risk for severe ovarian hyperstimulation syndrome: an observational cohort study.
Lainas GT; Lainas TG; Sfontouris IA; Venetis CA; Bosdou JK; Chatzimeletiou A; Grimbizis GF; Tarlatzis BC; Kolibianakis EM
Reprod Biomed Online; 2020 Jan; 40(1):168-175. PubMed ID: 31839394
[TBL] [Abstract][Full Text] [Related]
19. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.
Haas J; Kedem A; Machtinger R; Dar S; Hourvitz A; Yerushalmi G; Orvieto R
J Ovarian Res; 2014 Apr; 7():35. PubMed ID: 24694069
[TBL] [Abstract][Full Text] [Related]
20. Delayed Start Versus Conventional GnRH Antagonist Protocol in Poor Responders Pretreated With Estradiol in Luteal Phase: A Randomized Controlled Trial.
Maged AM; Nada AM; Abohamila F; Hashem AT; Mostafa WA; Elzayat AR
Reprod Sci; 2015 Dec; 22(12):1627-31. PubMed ID: 26045549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
